Enveric Biosciences Inc. - news published 259 - readings 4.421

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addictio ...

Continue reading
23.03.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 - Form 8-K

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass., March 23, 2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company ...

Continue reading
23.03.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications - Form 8-K

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications First-in-human clinical trial investigating Enveric's lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023 CAMBRIDGE, Mass., March 21, 2023 - Enveric Biosciences (NASDAQ: ENVB) (&q ...

Continue reading
21.03.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery - Form 8-K

Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass., March 14, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnolo ...

Continue reading
14.03.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Form 8-K

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. CAMBRIDGE, Mass., February 28, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Com ...

Continue reading
01.03.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addicti ...

Continue reading
28.02.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Form 8-K

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass., February 23, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric&quo ...

Continue reading
23.02.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depressio ...

Continue reading
23.02.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Enveric Biosciences Inc. published this content on 22 February 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 22 February 2023 13:01:26 UTC .

Continue reading
22.02.2023